PKPD modelling and simulation is now “ingrained” in drug development and its importance will continue to grow as approaches evolve in “very exciting” coming years, according to an Icon VP.
Housing cGMP labs in the same Pennsylvania, US facility as its vaccine and biologics centre is allowing PPD to offer more integrated services.
The McCrone Group says pharmaceutical industry need for “quick and dirty” QA/QC solutions in the laboratory and on the factory floor is driving growth of the market for bench-top microscopy.
US Contract research laboratory Metrics reveals that benzophenone, a component used in varnish on labels, is able to migrate through HDPE bottles to reach the pills inside.
Recognition of glass vial quality issues is supporting interest in West’s analytical capabilities and Crystal Zenith (CZ) products, new sizes of which are being developed, said a company VP.
Demand for high-end capsule filling technologies, particularly those used for early clinical development projects, has increased in 2010 according to Capsugel.
SCM Pharma says demand for specialised contract manufacturing services is growing as the pharma industry focuses on niche indications, biologics and the development of potent medicines.
Newly-formed Gateway Analytical is confident its service offering, employees’ experience and ties to its parent company will allow it to grow despite a challenging operating environment.
Globalisation is the main challenge to drug supply chain security according to USP scientist Desmond Hunt, who says greater collaboration is the key to maintaining product integrity
Icon is adding protein and peptide profiling to its biomarker capabilities through a strategic alliance with Proteome Sciences.
Quotient Clinical and Bend Research have teamed up to tackle solubility issues in early clinical development.
PRA International says its new bioanalytical services laboratory in Lenexa, Kansas offers clinical customers streamlined services.
Adding Indian cGMP HPAPI capabilities builds on Arch’s strategy of differentiating through technology and establishes it in an emerging and profitable sector.
Drug industry demand for chemical intermediates and development projects has rebounded significantly in the last 12 months according to UK group Endeavour Specialty Chemicals.
Rx-360 expects membership numbers to “snowball” in the coming year as it looks to build on progress made in establishing the consortium.